AI assistant
Quantum Genomics — Capital/Financing Update 2014
Sep 2, 2014
1617_iss_2014-09-02_e6079479-8a4c-456a-bbf2-cae950b9cb16.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Massy – September 2, 2014
Quantum Genomics receives financial aid from Bpifrance (France Public Innovation Bank) for its research program evaluating combinations of its new class of molecules with other anti-hypertensive compounds
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it received a 260 K€ subsidized financing from Bpifrance for its research program assessing combinations of BAPAIs (Brain Aminopeptidase A Inhibitors) with other anti-hypertensive compounds.
Because, in many cases, a combination of treatments is necessary to control blood pressure in patients, Quantum Genomics intends to develop and test, as are doing most of pharmaceutical companies which launched in recent years anti-hypertensive drugs onto the market, the clinical efficiency of several possible combinations of its product QGC001 with other anti-hypertensives.
The synergistic actions expected from the effects of QGC001 and those of other antihypertensive agents may allow to reduce treatment doses and minimize side effects. More importantly, the association of QGC001 with other anti-hypertensives may become a therapeutic solution for the poorly or totally not controlled patients, who represent more than 50% of individuals treated by existing anti-hypertensive drugs.
The financial support provided by BPI France applies to a research program with a 19 months duration (June 2014 to December 2015) and based on 2 modules:
- Preclinical pharmacology studies in spontaneously hypertensive rats to assess the efficiency of QGC001 in combination with compounds representing four main classes of anti-hypertensive drugs: Diuretics, Calcium Channel Blockers, Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Antagonists (ARAs).
- Regulatory preclinical studies aiming to demonstrate the bioavailability and safety of QGC011, a combination of QGC001 with Enalapril (ACE inhibitor), to supplement the promising results already obtained.
With this new public aid, the total amount of financings received from Bpifrance and ANR (National Research Agency) by Quantum Genomics since its inception is 1.8 M€.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.
Quantum Genomics is listed on Alternext in Paris (ISIN code: FR0011648971 - ticker ALQGC).
Contacts
| Quantum Genomics | Quantum Genomics | ACTUS |
|---|---|---|
| Lionel Ségard | Marc Karako | Jean-Michel Marmillon |
| CEO | CFO - Investor relations | Presse relations |
| +33 (0)1 60 13 76 80 | +33 (0)1 60 13 76 84 | +33 (0)1 53 67 07 80 |
| [email protected] | [email protected] |